Anteris Technologies (AVR) has launched a US$20 million (A$27.5 million) placement to US-based investment management firm Perceptive AdvisorsThe healthcare stock penned an agreement with Perceptive Life Sciences Master Fund for the placement, which will see Perceptive become Anteris’ largest shareholderAnteris will issue 1.84 million shares at $15 each, representing a 20 per cent discount to its last closing price on February 28The funds will be used to develop its 3D single-piece aortic valve replacement, DurAVR, to treat patients with aortic stenosis in upcoming clinical trialsAnteris shares are up 3.11 per cent to trade at $19.25
Anteris was up 3.11 per cent to trade at $19.25 at 1:15 pm AEDT.
Anteris Technologies (ASX:AVR) gets US$20m boost for DurAVR development,
https://themarketherald.com.au/anteris-technologies-asxavr-gets-us20m-boost-for-duravr-development-2022-03-02/?jwsource=cl
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$6.27 |
Change
0.360(6.09%) |
Mkt cap ! $97.17M | |||
| Open | High | Low | Value | Volume |
| $5.93 | $6.30 | $5.91 | $107.9K | 17.39K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3500 | $6.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.27 | 200 | 1 |
View Market Depth
| Last trade - 15.42pm 27/06/2025 (20 minute delay) ? |
| AVR (ASX) Chart |